Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm glad the word is getting out and people are finally noticing this stock
Aethlon Medical (NASDAQ:AEMD) shares are surging 28% after publishing results from a study of its resin that captures Covid-19 variants.
Wow empty board. Shame . GC is awesome . $aemd and no value from this app / forum
Monkey pox funded Billions over @2 today I believe
Room to run
About Aethlon and the Hemopurifier----
Aethlon Medical is a medical technology company developing the Hemopurifier, a therapeutic blood filtration system indicated for infectious diseases and cancer. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing a proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases.
I'm thinking the same thing...15.4 million shares outstanding. Over 18 million bought or sold in 2 days.
Do you think somebody's loading up? Price hasn't taken off yet.
monkey pox ????? $AEMD
AEMD
Aethlon Medical Inc
1.05
0.0304 (2.98%)
Volume: 206,465
Day Range: 1.00 - 1.0599
Bid: 1.01
Ask: 1.05
Last Trade Time: 5:19:24 PM EDT
Total Trades: 427
AEMD Detailed Quote
Aethlon Medical Announces U.S. FDA Approval of Hemopurifier COVID-19 Study Protocol Amendment
https://d1io3yog0oux5.cloudfront.net/_29959e27d7a01d508073adc278ab5d61/aethlonmedical/news/2022-07-11_Aethlon_Medical_Announces_U_S_FDA_Approval_of_448.pdf
July 11, 2022
Approval eliminates the requirement for previous dialysis treatment, potentially enabling accelerated enrollment in the ongoing clinical study
SAN DIEGO, July 11, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an amendment to the protocol of its ongoing clinical trial investigating the Aethlon Hemopurifier® for patients with severe COVID-19. The newly approved protocol amendment eliminates the inclusion criteria that patients must have a dialysis catheter in place and have tolerated dialysis at the time of screening.
"We are pleased that the FDA has approved our protocol amendment for the COVID-19 trial," said Charles J. Fisher, Jr., M.D., Chief Executive Officer of Aethlon Medical. "We anticipate that this protocol amendment will enable us to enroll patients at an increased rate now that dialysis treatment is no longer a study requirement. We look forward to providing access to this potentially life-saving therapy to patients in need."
The Aethlon Hemopurifier is a therapeutic blood filtration system that can bind and remove life-threatening viruses and harmful exosomes from blood. Aethlon is currently evaluating the safety and feasibility of the Hemopurifier in an active Early Feasibility Study (EFS), analogous to a Phase 1 clinical trial for a drug or biologic, which is designed to enroll up to 40 severe COVID-19 patients [NCT04595903]. Aethlon recently announced that the first patient has completed Hemopurifier treatment in the trial and that there are nine hospitals actively screening patients.
"We have learned from our study sites during screening, from data presentations and from thought leaders in the field that the incidence of COVID-19-induced kidney injury, resulting in the need for kidney replacement therapy (KRT), has decreased dramatically during the course of the pandemic," said Steven LaRosa, M.D., Chief Medical Officer of Aethlon Medical. "As such, we worked closely with the FDA to construct updated wording in the protocol and informed consent that allows patients to participate in the study who do not already require KRT yet still protects patient safety."
"This protocol amendment will need to be submitted by the investigative teams and approved by the IRB at each clinical site; a process that can take several months. It also remains to be seen if the prevailing COVID-19 variant BA.5 will result in increased ICU admissions; a requirement of the clinical study," continued Dr. LaRosa.
Aethlon is working with PPD, Inc., an established contract research organization (CRO), to advance this clinical study.
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical technology company developing the Hemopurifier, a therapeutic blood filtration system indicated for infectious diseases and cancer. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing a proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases.
The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. Under an Investigational Device Exemption (IDE) application, the FDA approved a single site, open-label Early Feasibility Study (EFS) to evaluate the Hemopurifier for reducing cancer-associated exosomes prior to the administration of standard-of-care pembrolizumab (KEYTRUDA®) in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. The EFS is being conducted at the University of Pittsburgh Medical Center Hillman Cancer Center.
The Hemopurifier also holds an FDA Breakthrough Device designation and an open IDE application related to the treatment of life-threatening viruses that are not addressed with approved therapies. A recent amendment to the IDE enabled Aethlon to implement a new EFS protocol to treat up to 40 COVID-19 patients at up to 20 clinical sites in the U.S. In two case studies of patients treated under Emergency Use (EU), the Hemopurifier demonstrated binding of SARS-CoV-2 spike protein and removal of SARS-CoV-2 virus from the circulation of a human patient.
Aethlon Medical Inc (AEMD)
1.17 ? -0.09 (-7.14%)
Volume: 419,741 @06/03/22 7:59:33 PM EDT
Bid Ask Day's Range
1.16 1.25 1.15 - 1.25
AEMD Detailed Quote
I like Spectral Medical of Canada. I have for a long time. I like companies that those with the most intimet of intel like...especially if they like it A LOT.
AEMD seems pretty good too. I like their management.
Hemopurifier has been used safely, over 150 times in 36 patients.
Sure seems like somebody wants some cheapies..
You will hear. But it wont sound good. DILUTION OF DEATH
Abstract
https://www.biorxiv.org/content/10.1101/2022.04.27.489436v1
The Coronavirus-19 (COVID-19) pandemic due to the SARS-CoV-2 virus has now exceeded two years in duration. The pandemic has been characterized by the development of a succession of variants containing mutations in the spike protein affecting infectiousness, virulence and efficacy of vaccines and monoclonal antibodies. Resistance to vaccination and limitations in the current treatments available require the ongoing development of therapies especially for those with severe disease. The plant lectin Galanthus nivalis binds to mannose structures in the viral envelope. We hypothesized that viral binding should be unaffected by spike protein mutations. Known concentrations of seven clinically relevant SARS-CoV-2 variants were spiked in medium and passed three times over columns containing 1 gm of GNA affinity resin. Percent decrease in viral titer was compared with a control sample. Viral capture efficiency was found to range from 53 to 89% for all variants. Extrapolation indicated that an adult Aethlon Hemopurifier® would have more than sufficient binding capacity for viral loads observed in adult patients with severe COVID-19 infection.
Competing Interest Statement
This study was funded by Aethlon Medical, Inc. Aethlon Medical provided the materials and GNA affinity resin to perform the study. Authors SPL and CSF are employees of Aethlon Medical, Inc.
Aethlon Medical Inc (AEMD)
1.05 ? -0.04 (-3.67%)
Volume: 34,569 @04/29/22 7:04:49 PM EDT
Bid Ask Day's Range
1.04 3.97 1.07 - 1.1271
AEMD Detailed Quote
Aethlon Medical Inc (AEMD)
1.05 ? -0.04 (-3.67%)
Volume: 34,569 @04/29/22 7:04:49 PM EDT
Bid Ask Day's Range
1.04 3.97 1.07 - 1.1271
AEMD Detailed Quote
Aethlon Medical Inc (AEMD)
1.05 ? -0.04 (-3.67%)
Volume: 34,569 @04/29/22 7:04:49 PM EDT
Bid Ask Day's Range
1.04 3.97 1.07 - 1.1271
AEMD Detailed Quote
Aethlon Medical Inc (AEMD)
1.29 ? -0.01 (-0.77%)
Volume: 61,727 @03/11/22 5:35:58 PM EST
Bid Ask Day's Range
1.23 1.3 1.21 - 1.34
AEMD Detailed Quote
They seem to be spending alot of money to move into bigger offices with a larger lab and a new manufacturing place.
Hopefully we'll hear of more good results with the Hemopurifier.
How To Be Your Own Corona-COVID Doctor !!
To Save You & Family & Children From Any Virus !
https://investorshub.advfn.com/I-have-or-had-CoronaVirus-Covid19-38361/
.
United States Coronavirus Cases: 77,966,691 02-06-2022 vs 4,290,235
Deaths:
925,655 vs 149,046
Recovered:
47,900,252 vs 2,040,513
Daily Cases Graph - Daily Deaths Graph
Projections
WORLD / COUNTRIES / UNITED STATES
Last updated: February 06, 2022, 02:24 GMT
https://www.worldometers.info/coronavirus/country/us/
https://www.worldometers.info/
United States Coronavirus Cases:6,172,272,Deaths:149,046,covered:
3,422,996
https://www.worldometers.info/coronavirus/country/us/
https://www.worldometers.info/
COVID-19 CORONAVIRUS PANDEMIC Last updated: February 06, 2022, 02:24 GMT
Weekly Trends - Graphs - Countries - News
https://www.worldometers.info/
Coronavirus Cases: 394,009,220 vs 33,342,491 Deaths
Coronavirus Cases: 394,009,220
view by country
https://www.worldometers.info/coronavirus/
Deaths: 5,752,512 vs Deaths: 1,002,974
Recovered: 312,798,399 vs Deaths: 1,002,974
Coronavirus Cases: 33,342,491 Deaths: 1,002,974 Recovered:24,655,268
$Coronavirus Cases:16,087,202,Deaths:645,309Deaths: 1,002,974
https://www.worldometers.info/coronavirus/
WAS
135,885 u.s.a.vs 4634 china deaths World Coronavirus Cases:12,442,037, Deaths:558,544,Recovered:7,258,661
https://www.worldometers.info/coronavirus
Aethlon Medical Inc (AEMD)
1.42 ? -0.02 (-1.39%)
Volume: 24,602 @02/04/22 7:45:59 PM EST
Bid Ask Day's Range
1.43 1.5 1.4 - 1.49
AEMD Detailed Quote
Has anyone heard from JL
Aethlon Medical Inc (AEMD)
3.36 ? 0.05 (1.51%)
Volume: 190,453 @11/05/21 6:33:04 PM EDT
Bid Ask Day's Range
3.2 7.86 3.22 - 3.38
AEMD Detailed Quote
Notice of effectiveness??? What does this mean.
I'm hoping we get some more news with earnings report next month. Updates on patients that were signed up for Hemopurifier, and more results.
thank you Aethlon Medical Inc (AEMD)
3.51 ? 0.11 (3.24%)
Volume: 655,705 @10/12/21 4:15:05 PM EDT
Bid Ask Day's Range
3.34 3.52 3.3 - 3.56
AEMD Detailed Quote
NAPA auto parts is achieving better results with their Fram PH8A filters from old Ford engines
AEMD patients apparently do not do too well
The good news is that Faucci may decide this is huge breakthrough news and require all school children to have one of these.
Pump a little 5W30 in those veins
Call me in the morning
AEMDuh
Aethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier®
October 12, 2021
SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced the publication of a manuscript in the peer-reviewed journal Frontiers in Medicine describing two cases of critically ill COVID-19 patients treated with the Hemopurifier®, Aethlon's therapeutic blood filtration system. The publication, titled "Removal of COVID-19 spike protein, whole virus, exosomes and exosomal microRNAs by the Hemopurifier® lectin-affinity cartridge in critically Ill patients with COVID-19 infection," is available here: https://www.frontiersin.org/articles/10.3389/fmed.2021.744141/full
The publication documents two critically ill COVID-19 patients receiving a combined total of nine, six-hour Hemopurifier® treatment sessions. These two patient case studies are notable because they are the first descriptions of the Hemopurifier® successfully removing exosomes, exosomal microRNAs, and SARS-CoV-2 virus in patients with COVID-19. In the first patient, exosome and exosomal microRNA removal was associated with improved coagulopathy, oxygenation, and clinical recovery. In the second patient, SARS-CoV-2 virus removal by the Hemopurifier® was demonstrated, but the patient expired because the disease was advanced and had triggered multiple organ system failures. The patient had completed Hemopurifier® treatment and passed away while receiving Continuous Renal Replacement Therapy (CRRT). Hemopurifier® treatment sessions were well tolerated by both patients without side effects.
"The emergence of COVID-19 variants has prompted an even greater need for innovative COVID-19 treatments. These results demonstrate that the Hemopurifier® can remove exosomes and viral particles related to COVID-19 from the blood stream in humans," said Charles J. Fisher, Jr., M.D., CEO of Aethlon Medical and an author of the manuscript. "We remain optimistic about our ongoing studies of the Hemopurifier® as a treatment for critical COVID-19 patients."
The safety and feasibility of the Aethlon Hemopurifier® is being evaluated in an active Early Feasibility Study, analogous to a Phase 1 clinical trial for a drug or biologic, that is designed to enroll up to 40 COVID-19 ICU patients [NCT04595903].
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical technology company developing the Hemopurifier®, a blood filtration system targeting life-threatening viral diseases and cancer. The Hemopurifier® has demonstrated the ability to remove exosomes and viral particles from the blood stream in human studies. The Hemopurifier® has potential applications in cancer and in severe viral diseases, where exosomes may promote immune suppression and tumor metastasis in cancer, and organ dysfunction in viral diseases. The Hemopurifier® holds two U.S. Food and Drug Administration (FDA) Breakthrough Device designations for the treatment of individuals with advanced or metastatic cancer and also for the treatment of life-threatening viral diseases that are not addressed with approved therapies.
The breakthrough device designation in cancer is indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. Under an Investigational Device Exemption (IDE) application, the FDA approved a single site, open-label Early Feasibility Study (EFS) to evaluate the Hemopurifier® for reducing cancer-associated exosomes prior to the administration of standard-of-care pembrolizumab (KEYTRUDA®) in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. The EFS is being conducted at the University of Pittsburgh Medical Center Hillman Cancer Center.
The breakthrough device designation in viral disease is for an open IDE application related to the treatment of life-threatening viruses that are not addressed with approved therapies. The Company is conducting a clinical trial approved by the FDA to treat up to 40 COVID-19 patients at up to 20 clinical sites in the U.S. In two case studies of patients treated under Emergency Use Authorization (EUA), the Hemopurifier® demonstrated binding of SARS-CoV-2 spike protein and removal of SARS-CoV-2 virus and exosomal microRNAs associated with organ disfunction from the circulation of human patients.
Additional information can be found at www.AethlonMedical.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to enroll patients in and successfully complete trials in the Early Feasibility Studies in COVID-19 patients, the Company's ability to successfully treat patients under any Emergency Use pathway, the Company's ability to successfully complete development of its Hemopurifier, the Company's ability to raise additional funds, and other potential risks. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2021, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.
Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Media Contact:
Tony Russo, Ph.D.
Russo Partners, LLC
tony.russo@russopartnersllc.com
212-845-4251
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
212-966-3650
Aethlon Medical Inc (AEMD)
3.6 ? -0.14 (-3.74%)
Volume: 218,247 @10/08/21 7:50:35 PM EDT
Bid Ask Day's Range
3.6 3.73 3.58 - 3.8
AEMD Detailed Quote
Aethlon Medical Inc (AEMD)
4.7 ? 0.9 (23.68%)
Volume: 96,403,838 @09/22/21 7:59:52 PM EDT
Bid Ask Day's Range
4.69 4.7 4.68 - 5.9899
AEMD Detailed Quote
AEMD - Tuesday Rundown, Wednesday Expectations
AEMD....and longevity....
The most important technology is not 5G, not EVs or terra farming Mars..
The next most important frontier is going to be extending lifespan. At present there is no hard evidence that death is guaranteed by age a hundred , or even 130 years. The truth is there is ample proof that none of the aging factors has a definable cut off number...
At present scientists have identified factors that hasten our way to "Dusty Death...Its just that although the knowledge would seem paramount..It is known only to a relative few scientist in the field...One issue is that "old cells" actually can and do secrete chemicals into the bloodstream. There are other factors such as alteration in the DNA (transpondors)
Thanks, i always appreciate your responses as they are clearly written and brought down to a level that makes it digestible for a layman.
Hope you are doing well.
newbie...
Your question..Quote,," how does the purifier distinguish between a particle carrying a "message" spreading a disease vs all the other particles carrying on normal functions that contribute to cellular health?"
Ans; It doesn't...The problem is bad things (cancer and Viruses or their genetic information attacks cell functions or uses them to multiply. The heme purifier does not go after the cancers, viruses or their DNA..It goes after the cloaking system which prevents the immune and inflammatory systems from going after these dangerous invaders. If if the purifier uncovers a beneficial passenger...there will be no attack on the non invader as long as it is not foreign matter...
":>) JL
Aethlon Medical Inc (AEMD)
3.92 ? 0.1 (2.62%)
Volume: 561,129 @08/13/21 7:58:34 PM EDT
Bid Ask Day's Range
3.91 3.92 3.76 - 4.06
AEMD Detailed Quote
Gbert....
"Why couldn’t the PPS increase correlate with the recent spike in COVID cases?"
Good question...
The "New cases" are "the variant"...Which is much more contagious but much less potent. Think...Like what we use to call a "cold"...
In the field of virology there is a well known phenonium called "pass through"...That is new case are being transmitted by patients with the virus so the recipients are getting second generation viruses and these Have passed through one host...The rule is the viruses lose their virulence with each "pass through". This is true of virtually all viruses. including Ebola...It is probably a survival factor for the viruses and prevents them from killing all the hosts...which would be the end for the viruses..
Please keep in mind most of the discussion of the so called endemic/pandemic...is from the media. who want to scare the shit out of the population so they will stay glued to the Tube and get higher ratings and more ad dollars...same for our crooked politicians who want to fool you into thinking you can not live without following their sage advice. and you better damn well re elect them because Trump caused the plague...and if he comes back you are all going to die...
":>) JL
Could you imagine not selling at 11.00. Lol
Why couldn’t the PPS increase correlate with the recent spike in COVID cases?
Hi...
Did I mention the fact I thought this was going to be a very big deal, And I know I posted that I really liked this stock...and was taking a big position. Well this is doing better than I thought...
It seems unlikely that a two person trial...would be enough evidence to draw any kind of conclusion. But in rare situations two patients can be enough and sometime one patient is plenty. And this is the situation with the two terminal patients one who was treated with the hemo purifier and one who didn't get the purifier...The won who was treated went home. Walked right out of the hospital. The other died...The important thing here is the clinicians considered both of these patients terminal (beyond the hope that any current therapy could cure them.) and trust me...I am a former combat surgeon in Vietnam. and have worked in a burn unit and a surgical intensive care unit.. and I can tell you doctors who work there can tell with a great deal of certainty who is going to make it; and who wont.
My guess (since we don't have any explanation) why the price went up is that one of AEMD's other small trials is validating the earlier experience...
GLA ":>) JL
Im a holder....I think its getting ready here to BOOM!
Followers
|
233
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
18503
|
Created
|
11/19/04
|
Type
|
Free
|
Moderators |
At Aethlon Medical, we are a leading developer of immunotherapeutic technologies to combat infectious disease and cancer. To augment the body's natural immune defenses,
the Aethlon Hemopurifier® eliminates life-threatening disease targets that are often shielded from the immune system and not well addressed by traditional drug therapies.
The technology captures circulating viruses, bacterial toxins and cancer promoting exosomes through affinity attachment to a unique structure cloaks these targets from immune detection.
At present, the Hemopurifier® is being advanced under an FDA approved clinical study. Aethlon is also the majority owner of Exosome Sciences, Inc.,
a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threatening diseases.
Exosome Sciences, Inc., in collaboration with majority shareholder Aethlon Medical,
is focused on the discovery of exosomal biomarker candidates to diagnose and monitor life-threatening diseases.
The proprietary Enzyme-Linked Lectin-Specific Assay (ELLSA™) serves as a platform to isolate exosomal biomarkers from a wide-range of bodily fluids.
In preliminary studies, ELLSA™ demonstrated the ability to isolate exosomes from urine, which resulted in high-sensitivity detection of HIV-infection.
Specific to neurological disorders, Exosome Sciences discovered TauSome™, an exosomal biomarker that may be the first non-invasive candidate to
detect Chronic Traumatic Encephalopathy (CTE) in living individuals. In a study of former National Football League (NFL) players,
TauSome levels were found to be significantly higher as compared to athlete control subjects who participated in non-contact sports.
TauSome levels also correlated with cognitive decline based standardized tests of memory and psychomotor speed. Visit www.exosomesciences.com for additional details.
Time Magazine named the Hemopurifier® a "Top 25 Invention" and a "Remarkable Advance in Healthcare" based on its use in treating Ebola virus.
Emerging pathogens pose a significant threat to mankind. Of the hundreds of viral pathogens known to be infectious to man, only a few are addressed with
proven antiviral drug or vaccine therapies. Beyond the looming threat of bioterrorism, a proliferation of international travel, urban crowding and global warming
is expected to accelerate the emergence of future pandemics. In response, the U.S. Department of Health and Human Services (HHS) has established an initiative
to support platform technology medical countermeasures with broad-spectrum capabilities. Based on preclinical studies and human treatment experiences, the Aethlon Hemopurifier® defines this initiative.
To date, Hemopurifier therapy has been administered to individuals infected with Ebola virus, Hepatitis C virus (HCV) and the Human Immunodeficiency virus (HIV).
In the case of Ebola, a remarkable response to a single administration of Hemopurifier therapy (comatose physician with multiple organ failure at the time), led to
Time Magazine naming the Hemopurifier to be one of the "Top 25 Inventions" as well as one of the "Eleven Most Remarkable Advances in Healthcare."
Beyond human treatment experiences, pre-clinical Hemopurifier studies have validated the broad-spectrum capture of numerous viral threats.
These include: Chikungunya, Dengue and West Nile virus, as well as Vaccinia and Monkey pox, which serve as models for human Smallpox infection.
Specific to pandemic influenza threats, Aethlon has validated the capture of H5N1 avian flu, H1N1 swine flu, and the reconstructed 1918 influenza virus,
which represents a model for the strain of influenza that killed an estimated 50 million victims in 1918 and 1919. In vitro studies of other viral threats are ongoing.
https://coronavirus.jhu.edu/map.html
================================================================================================================================================================================
================================================================================================================================================================================
================================================================================================================================================================================
*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |